NEWS

NEWS

News

NantKwest to Host 3rd Annual Investor/Analyst Day Highlighting A Record Number of 15 INDs Authorized in 2017 Covering 12 Tumor Types with First In-Human Clinical Data of Safety and Early Signs of Clinical Activity of the Nant Cancer Vaccine

January 4, 2018 — Culver City, California — NantKwest (NASDAQ: NK), a pioneering, next generation, clinical-stage immunotherapy company focused on harnessing the unique power of the human immune system using natural killer (NK) cells to treat cancer,...

read more

Archives

Media Contact:

Jen Hodson
NantKwest
Telephone: 562-397-3639
Email: Press@NantKwest.com